CAMBRIDGE, Mass.--(BUSINESS WIRE)--Altus Pharmaceuticals Inc. (NASDAQ: ALTU) today announced that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for ALTU-237, an orally-delivered crystalline formulation of an oxalate-degrading enzyme. Altus has designed ALTU-237 for the treatment of hyperoxalurias and the possible prevention of recurrent kidney stones in individuals with a high risk or history of kidney stones. Following the FDA review period, the Company intends to initiate a Phase I human clinical trial to assess the safety of ALTU-237.
